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ABSTRACT 42 
 Purpose: Skin toxicities associated with anti-epidermal growth factor receptor 43 
(EGFR) antibodies, have a profound effect on the continuation of treatment. We assessed the 44 
efficacy and safety of vitamin K1 (VK1) ointment for acneiform eruptions induced by anti-45 
EGFR antibody treatment. 46 
 Methods: The VK1 ointment was applied to one-half of an affected area and placebo 47 
ointment was applied to the other half twice a day for 8 weeks, with photography and clinical 48 
evaluation being performed every two weeks. The primary endpoint was the change of the 49 
VK1/placebo ratio for the number of acneiform eruptions counted by an independent 50 
dermatologist between the onset and end of the treatment period. 51 
 results: A total of 30 patients were enrolled. The mean VK1/ placebo ratio for the 52 
number of acneiform eruptions between the onset and end of the treatment period was -0.158 ± 53 
0.680 and 0.146 ± 0.575, respectively, which was not statistically significant (P = 0.069). The 54 
mean number of acneiform eruptions at each treatment period at the VK1 and placebo 55 
application sites was gradually decreased according to the treatment period.  56 
 5 
 conclusion: VK1 ointment was not effective against acneiform eruptions induced by 57 
treatment with cetuximab or panitumumab. Reassessment of the VK1 concentration in the 58 
ointment and the endpoint of skin lesions is required before designing further studies.  59 
 60 
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INTRODUCTION 62 
Administration of cetuximab or panitumumab, antibodies targeting the epidermal growth factor 63 
receptor (EGFR), combined with cytotoxic chemotherapy is the standard regimen for patients 64 
with metastatic colorectal cancer of the K-ras wild type.1 A typical adverse effect induced by 65 
the anti-EGFR antibody therapy is skin toxicity because EGFR is not only expressed on tumor 66 
cells, but also on various other cells, including keratinocytes, sweat gland cells, basal cells, and 67 
the epithelial cells of hair follicles. Cutaneous symptoms occur in 80–90% of patients receiving 68 
anti-EGFR antibody treatment and are severe in about 15% of the cases. It has been reported 69 
that the onset and severity of cutaneous symptoms are correlated with the tumor response and 70 
survival rate.2,3 Among the various cutaneous symptoms, acneiform eruptions often occur on 71 
the nose, cheek, jaw, forehead, back, and/or chest within 3 weeks of starting the anti-EGFR 72 
antibody therapy. These skin lesions cause physical and mental discomfort that can influence 73 
both the continuation and intensity of the treatment, thus, having an effect on the clinical 74 
outcomes.4 The standard management for acneiform eruptions induced by anti-EGFR antibody 75 
therapy involves prophylactic administration of tetracycline antibiotics, moisturizing agents, 76 
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and topical steroids based on the results of several previous randomized-controlled trials4–13 and 77 
a meta-analysis.14 However, the therapeutic methods needed for the management of skin 78 
toxicity observed in the treatment with anti-EGFR antibody remains an unresolved issue in 79 
clinical practice. 80 
Vitamin K (VK) is a group of fat-soluble vitamins. Vitamin K1 (VK1) is found in the 81 
dietary components, particularly in green leafy vegetables, and is metabolized to vitamin K2 82 
via vitamin K3 (VK3) in humans.15 Beier et al16 reported EGFR activation and downstream 83 
signaling in human keratinocytes exposed to VK3. We, therefore, hypothesized that EGFR 84 
activation by short-term exposure to VK could counteract the inhibitory effect of cetuximab or 85 
panitumumab on this receptor, resulting in reducing the acneiform eruptions in patients 86 
receiving the anti-EGFR antibody therapy. In a clinical setting, topical VK1 ointment showed 87 
promising data of pre-emptive intervention before skin toxicity or treatment after the rash 88 
appeared, despite pilot studies of small sample size.17–19 However, to date, the treatment benefits 89 
of topical VK1 application have not been established in any randomized, double-blind, placebo-90 
controlled prospective study. The strength of this study is that there is a reduced bias due to 91 
 8 
within-patient comparison. 92 
The present study was, therefore, designed to clarify whether VK1 ointment has the ability 93 
to reduce acneiform eruptions induced by anti-EGFR antibody therapy in Japanese patients with 94 
metastatic colorectal cancer.  95 
 96 
PATIENTS AND METHODS 97 
Patients 98 
Among the Japanese patients aged 20 years or older, receiving treatment with cetuximab 99 
or panitumumab, those who developed acneiform eruptions on the face or chest and gave 100 
written informed consent were eligible for this study. Patients who were using VK preparations 101 
or VK antagonists were ineligible. The study protocol was approved by the Institutional Review 102 
Board of the National Cancer Center Hospital (approval number: 2011-196). This study was 103 
performed in accordance with the Declaration of Helsinki and the Ethical Guidelines for 104 
Medical and Health Research involving Human Subjects by the Ministry of Education, Culture, 105 
Sports, Science and Technology, and the Ministry of Health, Labour and Welfare of Japan.  106 
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 107 
Study Design and Objectives 108 
This was a placebo-control, double blind, randomized phase II study in which the efficacy 109 
and the safety of a VK1 ointment were evaluated in patients who developed acneiform eruptions 110 
during treatment with cetuximab or panitumumab. The study was registered with UMIN-CTR 111 
(UMIN000008099). 112 
 113 
Study Procedures 114 
Cetuximab was administered by intravenous infusion once a week, with the first dose (400 115 
mg/m2) being infused over 2 hours and the second and subsequent doses (250 mg/m2) infused 116 
over 1 hour. Panitumumab (6 mg/kg) was administered by intravenous infusion over 1 hour 117 
every 2 weeks, and it was used concomitantly with anticancer drugs (5-fluorouracil, irinotecan, 118 
and/or oxaliplatin) if deemed appropriate by the attending doctor. In those patients who 119 
developed acneiform eruptions after the administration of cetuximab or panitumumab and met 120 
the inclusion criteria for this study, two matching areas of the face (circle) or the chest 121 
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(diameter) (at least 10 cm × 10 cm) were marked on the right and left sides of the midline (one 122 
on each side). VK1 ointment was applied to right or left area following assignment and the 123 
placebo ointment was applied to the other area twice a day for 8 weeks, with photography and 124 
clinical evaluation performed every 2 weeks. VK1 and placebo ointment were applied from the 125 
evening of the treatment day.The treatment period was set at 8 weeks after the onset of skin 126 
eruptions in the study protocol. However, when cetuximab or panitumumab was discontinued 127 
before 8 weeks owing to disease progression or other events, the treatment period was modified 128 
to run from the onset of acneiform eruptions to the time of discontinuation. During the treatment 129 
period, the use of other topical preparations that could potentially influence the acneiform 130 
eruptions was not allowed at the sites where the test drug or placebo was being applied. There 131 
were no restrictions regarding the use of topical preparations at other sites and no restrictions 132 
on oral antibiotics. The use of topical, oral, and parenteral steroids was prohibited during the 133 
treatment period, apart from oral and/or parenteral steroids as antiemetic therapy in patients 134 
receiving the anticancer drugs. 135 
 136 
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VK1 and Placebo Ointments 137 
The VK1 and placebo ointments used in this study were prepared as follows. The 0.1% 138 
VK1 ointment was prepared by thoroughly blending VK1 (100 mg) with white petrolatum (100 139 
g). After the coloring fluid was prepared by dissolving the required amount of yellow food-140 
grade coloring agent in purified water (2.5 mL), the placebo ointment was prepared by 141 
thoroughly blending the coloring fluid with white petrolatum (100 g). 142 
The VK1 ointment was light-sensitive and patients were instructed to store it in a cool and 143 
dark place, with the expiration date set at two weeks after the preparation. Stability testing was 144 
performed using some randomly selected containers of the VK1 ointment to evaluate whether 145 
the VK1 content was maintained over time.  146 
 147 
Blinding 148 
In this study, the patients, doctors, and pharmacists acting as clinical research coordinators 149 
(study pharmacists) were blinded to the treatment assigned. The VK1 and placebo ointments 150 
used in this study were indistinguishable with regard to appearance and each ointment was 151 
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randomly placed into a container labeled “A” or “B”. The study pharmacists instructed the 152 
patients to apply the ointment in container “A” at the site on the right side and the ointment in 153 
container “B” on the left side (Figure 1). The drug assignment list was sealed and was kept 154 
securely by the study drug assignment manager until end of the study.  155 
 156 
Endpoint 157 
The primary endpoint was the change of the VK1/placebo ratio for the number of 158 
acneiform eruptions counted by an independent dermatologist between the onset and end of the 159 
treatment period. Patients were given diaries to record the daily application of the study drugs, 160 
other ointments used concomitantly (if any), and administration of antibiotics (if any), and these 161 
diaries were reviewed to assess the drug use and compliance. For evaluation of acneiform 162 
eruptions, a dermatologist who was not involved in the study counted the number of eruptions 163 
at the evaluation sites on photographs taken at each time of evaluation. In addition, the patient’s 164 
attending doctor evaluated the eruptions by using Common Terminology Criteria for Adverse 165 
Events (CTCAE) v4.0 and the Multinational Association of Supportive Care in Cancer 166 
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(MASCC) scale every 2 weeks as secondary endpoints (Supplemental Table S1). The 167 
application of the ointments was checked from the patients’ diaries. A compliance rate of 100% 168 
was defined as the patient applying the study drugs to the sites twice daily every day throughout 169 
the treatment period. 170 
 171 
Statistical Analysis 172 
The data are shown as means and standard deviation. The ratio of the number of acneiform 173 
eruptions at the VK1 site to the number at the placebo site was calculated as follows: 174 
VK1/placebo ratio = {(number of acneiform eruptions at the placebo site after treatment) – 175 
(number of acneiform eruptions at the VK1 site after treatment)}/(number of acneiform 176 
eruptions at the placebo site after treatment). The mean VK1/placebo ratio for the number of 177 
acneiform eruptions between the onset and end of the treatment period was analyzed by paired 178 
t-test. In addition, the mean number of acneiform eruptions at 0, 2, 4, 6, and 8 weeks after the 179 
treatment at the VK1 and placebo sites was analyzed by one-way analysis of variance (ANOVA) 180 
followed by Dunnett’s test. On the other hand, the proportion of patients who had eruptions ≥ 181 
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Grade 2 based on CTCAE v4.0 and ≥ Grade 2A based on MASCC scale between at the onset 182 
and 8 weeks after the treatment at the VK1 and placebo sites was analyzed by Fisher’s exact 183 
test. All analyses were performed using JMP software version 14.2.0 (SAS Institute, Tokyo, 184 
Japan). All P values were two-tailed, and P < 0.05 was considered significant.  185 
The number of patients required for this study was calculated using the following 186 
assumptions: the difference between the VK1/placebo ratio at the start of treatment and at the 187 
end of treatment was 0.25, the standard deviation of the difference was 0.4, the α error was set 188 
at 0.05 (two-sided), and the β error was set at 0.1. Accordingly, the number of patients required 189 
was estimated to be 27 patients, and the target number of patients was set at 30.  190 
 191 
RESULTS 192 
Patient Characteristics 193 
As shown in Figure 2, 30 patients were enrolled from August 2012 to August 2014. One 194 
patient did not receive the treatment as per the protocol because of early progression; the 195 
remaining 29 patients were available for analysis. All the participants were examined for the 196 
 15 
K-ras status, which was confirmed to be wild type. In eight of the 29 (27.5%) patients, anti-197 
EGFR antibody treatment was terminated before 8 weeks (at 2, 4, and 6weeks, there were 2, 3, 198 
and 3 cases respectively) due to disease progression. The baseline patient characteristics are 199 
listed in Table 1. 200 
 201 
Primary Endpoint 202 
The mean VK1/placebo ratio for the number of acneiform eruptions between the onset and 203 
end of the treatment period is shown in Figure 3. The values at the onset and end of the treatment 204 
were -0.158 ± 0.680 and 0.146 ± 0.575, respectively, and were not statistically significant (P = 205 
0.069). The photos at the start and end of protocol treatment are shown in Figure 4. 206 
 207 
Secondary Endpoint 208 
The mean number of acneiform eruptions at each treatment period on the VK1 and placebo 209 
sites is shown in Figure 5. The mean number of acneiform eruptions in both the groups was 210 
gradually decreased according to the treatment period, but there was no statistically significant 211 
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difference among all the periods on the VK1 site. On the other hand, there was statistically 212 
significant difference between 0 week and 4 and 8 weeks on the placebo site (P = 0.042 and P 213 
= 0.011, respectively). In addition, the proportion of patients who had eruptions ≥ Grade 2 based 214 
on CTCAE v4.0 between the onset and 8 weeks on the VK1 and placebo site was 34.5% and 215 
19.0%, respectively, which was not statistically significant (P = 0.341). In contrast, the 216 
proportion of patients who had eruptions ≥ Grade 2A based on the MASCC scale between the 217 
onset and 8 weeks on the VK1 site was 93.1% and 57.1%, respectively, which was statistically 218 
significant (P = 0.004). Similar results were obtained for the placebo site, 89.6% and 66.7%, 219 
respectively, which was statistically significant (P = 0.073). 220 
 221 
Compliance with the Study Treatment 222 
The compliance rate exceeded 90% in 19 of the 29 patients (66%), whereas it was 70–90% 223 
in six patients (21%) and < 50% in three patients (10%). There was no difference in the number 224 
of ointment applications between the right and left sides in any of the patients. In one patient, 225 
data on the use of the ointments were missing. The mean amount of VK1 and placebo ointment 226 
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used over two weeks was 18.21 g (range: 0.5–100 g) and 18.51 g (range: 0–100 g), respectively. 227 
 228 
Adverse Effects 229 
No adverse effects that were thought to be caused by the VK1 or placebo ointments were 230 
observed. To evaluate the systemic effect of VK1 ointment, prothrombin time- international 231 
normalized ratio (PT-INR) was measured in 25 of the 29 patients. The PT-INR values were 232 
within the normal range in all the patients before the start of the study treatment and also during 233 
the treatment. 234 
 235 
DISCUSSION 236 
To date, there has been limited information available regarding the therapeutic benefit of 237 
supportive therapy for skin toxicity induced by the anti-EGFR antibody therapy in a clinical 238 
practice setting. To the best of our knowledge, the present study is the first randomized, double-239 
blind, placebo-controlled phase II design for checking the efficay and safety of VK1 ointment 240 
for cetuximab or panitumumab-induced acneiform eruptions. Futhermore, VK1 ointment was 241 
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not effective against acneiform eruptions induced by cetuximab or panitumumab. The present 242 
findings, therefore, suggest that reassessment of the VK1 concentration in the ointment and the 243 
method of evaluating skin lesions is required before designing further studies. 244 
Our findings demonstrate that the primary endpoint did not show any significant difference 245 
between the VK1 and placebo ointment treatments with regard to the effect on acneiform 246 
eruptions induced by cetuximab or panitumumab. The present approach in our hypothesis that 247 
EGFR activation by short-term exposure to VK could counteract the inhibitory effect of 248 
cetuximab or panitumumab on this receptor completely failed. However, several previous 249 
studies reported that topical VK1 ointment had promising efficacy of pre-emptive intervention 250 
before skin toxicity or treatment after the rash appeared, despite pilot studies having a small 251 
sample size.17–19 Our data for VK1 efficacy were inconsistent with those of Ocvirk et al,17 who 252 
reported the improvement of skin rash of all grades after a median of 18 days with no adverse 253 
effects in 30 metastatic colorectal cancer patients receiving cetuximab. Differences in the nature 254 
of the study design and the methodology applied could account for discrepancies between both 255 
the results. Ocvirk et al17 also reported that VK1 cream alone was enough to manage skin 256 
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toxicity in patients with Grade 1 acneiform eruptions. Taken together, it seems likely that VK1 257 
cream may be effective on cetuximab or panitumumab-induced acneiform eruptions of Grade 258 
1, but not in the case of severe skin toxicity more than Grade 2.  259 
In general, adverse events caused by anticancer drugs are evaluated using CTCAE. 260 
However, CTCAE does not appropriately evaluates acneiform eruptions because only the 261 
percentage of the body surface area affected by eruptions is assessed, whereas symptoms such 262 
as tenderness and pruritus are not considered. Since the effect of acneiform eruptions on the 263 
patient is influenced by involvement of visible sites such as the face rather than by the total 264 
area, evaluation using CTCAE can not accurately determine the severity of the rash. 265 
Accordingly, we evaluated the efficacy of VK1 ointment based on the change in the number of 266 
eruptions counted by an independent dermatologist. Each patient’s attending doctor also 267 
evaluated the acneiform eruptions by using CTCAE, by counting the number of eruptions, and 268 
using the MASCC scale, which assesses the presence or absence of symptoms such as 269 
tenderness and pruritus. However, none of these evaluations indicated that VK1 ointment could 270 
improve cutaneous symptoms compared with the placebo ointment. This study is the first 271 
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within-patient comparison in which individual patients were randomized for application of the 272 
VK1 ointment to the right or left side of an affected site, whereas the placebo ointment was 273 
applied to the other side. If the patients are assigned to a test drug or placebo group when 274 
evaluating a topical preparation, application of the ointment can vary between patients and it 275 
becomes difficult to determine the efficacy of the test drug. In our study, the ointment containers 276 
were collected after use to check the amount of ointment applied. Although the amount varied 277 
between patients, they were blinded to the assignment of ointment. There was no marked 278 
differences between the amounts of VK1 and placebo ointments used on each side by a single 279 
patient. We observed that the number of acneiform eruptions decreasaed in both groups (Fig.4); 280 
this could be attributed to the moisturuizing effect of white petroleum. This method of blinded 281 
within-patient comparison may be useful to reduce bias.   282 
The present study has several limitations; the first was the concomitant use of antibiotics. In 283 
this study, the use of topical steroids was prohibited so that the efficacy of VK1 ointment could 284 
be evaluated more accurately, but antibiotics and moisturizing agents were allowed because it 285 
was ethically problematic to compel the patients to only use the VK1 ointment for 8 weeks. As 286 
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a result, we do not demonstrate any effect of the VK1 ointment on acneiform eruptions. While 287 
the number of acneiform eruptions was decreased at 8 weeks after the start of treatment, this 288 
might be due to the concomitant use of antibiotics and moisturizing agents, and the petrolatum 289 
base of the study drugs also has a moisturizing effect that might have improved the skin lesions 290 
over time. Second, the concentration of VK1 in the ointment was 0.1%, based on the previous 291 
studies. However, while the present study was underway, it was reported that 1% VK3 ointment 292 
was not effective for skin disorders in a study evaluating the effect of topical VK3 preparations. 293 
VK1 is found in the natural environment and is metabolized by vitamin-K epoxide reductase to 294 
vitamin K2 via vitamin VK3 in humans. There are no detailed data on the absorption rate of 295 
topical VK1 administered to the skin surface. VK3 has higher activity than VK1 and the LD50 296 
of VK3 is 50-times lower than that of VK1,20,21 suggesting that the VK1 concentration should 297 
be reconsidered for future studies. Exposure time is important for VK3 to activate EGFR, and the 298 
number of administrations of topical VK might have an affect on it15.  Third, the endpoint was the 299 
change in the VK1/placebo ratio for the number of acneiform eruptions, CTCAE, and MASCC 300 
scale. A recent study evaluating the pre-emptive effect of VK1 on acneiform eruptions also 301 
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found no significant difference in the primary endpoint, but VK1 improved the WoMo score, 302 
an alternative and more thorough skin toxicity scoring tool for acneiform eruptions from 5 303 
weeks.22 This suggests that the methods that were employed by us to evaluate the acneiform 304 
lesions in the present study might not have been sufficiently sensitive. 305 
 306 
CONCLUSIONS  307 
VK1 ointment was not effective against acneiform eruptions induced by treatment with 308 
cetuximab or panitumumab. Our data provide preliminary information about the Japanese 309 
population that can likely be translated to other Asian populations, and further highlights the 310 
need for additional research in this field. The reassessment of number of adminstrations and 311 
VK1 concentration in the ointment, as well as the endpoint of skin lesions, are required before 312 
designing further studies. 313 
 314 
ACKNOWLEDGEMENTS  315 
We would like to thank all the patients and medical staff at National Cancer Center Hospital, 316 
 23 
who kindly contributed to this study.  317 
Role of sponsor 318 
This was an investigator-initiated study. The sponsor of the study had no role in the study design, 319 
data collection, data analysis, data interpretation, or writing of the report. The corresponding 320 
author had full access to all the data in the study and had final responsibility for the decision to 321 





1. National Comprehensive Cancer Network (NCCN). Colon Cancer. Version 2. NCCN Clinical 326 
Practice Guidelines in Oncology; 2018. Available from: 327 
https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed August 6, 2018. 328 
2. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there 329 
a silver lining? J Clin Oncol. 2005;23:5235–5246. 330 
3. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and 331 
survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 332 
2004;22:3238–3247. 333 
4. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with 334 
panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a 335 
preemptive skin treatment regimen on skin toxicities and quality of life in patients with 336 
metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–1357. 337 
5. Hofheinz RD, Deplanque G, Komatsu Y, et al. Recommendations for the prophylactic 338 
management of skin reactions induced by epidermal growth factor receptor inhibitors in 339 
 25 
patients with solid tumors. Oncologist. 2016;21:1483–1491. 340 
6. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor 341 
inhibitor-induced skin rashes. Results of a placebo-controlled trial from the North Central 342 
Cancer Treatment Group (N03CB). Cancer. 2008;113:847–853. 343 
7. Jatoi A, Dakhil SR, Sloan JA, et al. Prophylactic tetracycline does not diminish the severity 344 
of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North 345 
Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer. 346 
2011;19:1601–1607. 347 
8. Scope A, Agero ALC, Dusza SW, et al. Randomized double-blind trial of prophylactic oral 348 
minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin 349 
Oncol. 2007;25:5390–5396. 350 
9. Deplanque G, Gervais R, Vergnenegre A, et al. Doxycycline for prevention of erlotinib-351 
induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line 352 
chemotherapy: a randomized, open-label trial. J Am Acad Dermatol. 2016;74:1077–1085. 353 
10. Melosky B, Anderson H, Burkes RL, et al. Pan Canadian rash trial: a randomized phase III 354 
 26 
trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth 355 
factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic 356 
lung cancer. J Clin Oncol. 2016;34:810–815. 357 
11. Arrieta O, Vega-González MT, López-Macías D, et al. Randomized, open-label trial 358 
evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-359 
small cell lung cancer patients. Lung Cancer. 2015;88:282–288. 360 
12. Lacouture ME, Keefe DM, Sonis S, et al. A phase II study (ARCHER 1042) to evaluate 361 
prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse 362 
events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27:1712–1718. 363 
13. Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of 364 
panitumumab in Japanese patients with metastatic colorectal cancer: hGCSG1001 study; 365 
J-STEPP. Future Oncol. 2015;11:617–627. 366 
14. Ocvirk J, Heeger S, McCloud P, et al. A review of the treatment options for skin rash induced 367 
by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. 368 
Radiol Oncol. 2013;47:166–175. 369 
 27 
15. Vitamin K. http://lpi.oregonstate.edu/mic/vitamins/vitamin-K. Accessed January 23, 2018. 370 
16. Beier JI, von Montfort C, Sies H, et al. Activation of ErbB2 by 2-methyl-1, 4-371 
naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine 372 
phosphatases. FEBS Lett. 2006;580:1859–1864. 373 
17. Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with 374 
vitamin K1 cream. Radiol Oncol. 2008;42:215–224. 375 
18. Tomková H, Pospíšková M, Zábojníková M, et al. Phytomenadione pretreatment in EGFR 376 
inhibitor-induced folliculitis. J Eur Acad Dermatol Venereol. 2013;27:514–519. 377 
19. Pinta F, Ponzetti A, Spadi R, et al. Pilot clinical trial on the efficacy of prophylactic use of 378 
vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients 379 
with metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13:62–67. 380 
20. Phytomenadione. http://www.merckmillipore.com/JP/ja/product/Vitamin-K1-381 
phytomenadione,MDA_CHEM-501890. Accessed August 6, 2018. 382 
21. Phytonadione. http://www.sciencelab.com/msds.php?msdsId=9926552. Accessed August 6, 383 
2018. 384 
 28 
22. Hofheinz1 R-D, Lorenzen S, Trojan J, et al. EVITA-a double-blind, vehicle-controlled, 385 
randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin 386 
toxicity. Ann Oncol. 2018;29:1010–1015. 387 
 29 
Figure legends 388 
Fig 1. Randomization 389 
A = Vitamin K1，B = Placebo or A = Placebo，B = Vitamin K1 random assignment (envelope 390 
method) 391 
 392 
Fig 2. CONSORT diagram 393 
 394 
Fig 3. Mean VK1/placebo ratio for the number of acneiform eruptions 395 
The data are shown as means and standard deviation. The mean VK1/placebo ratio for the 396 
number of acneiform eruptions between the onset and end of the treatment period was analyzed 397 
by paired t-test.  398 
 399 
Fig 4. The photos at the start and end of protocol treatment 400 
Fig 5. Mean number of acneiform eruptions at each treatment period 401 
The data are shown as means and standard deviation. The mean number of acneiform eruptions 402 
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at 0, 2, 4, 6, and 8 weeks after the start of treatment at the VK1 site and at the placebo site was 403 
analyzed by ANOVA followed by Dunnett’s test.  404 
  405 
 31 
Table 1. Patients’ characteristics at the baseline (N = 29). Data are given as number (%) 406 
of patients unless otherwise mentioned 407 
Characteristic Value 
Sex  
Male 21 (72.4%) 
Female 8 (27.6%) 
Age, median (range), years 64 (31–78) 
BSA, median (range), m2 1.63 (1.34–2.05) 
ECOG performance status  
0 13 (44.8%) 
1 15 (51.7%) 
2 1 (3.4%) 
Anti-EGFR antibody    
Cetuximab 17 (58.6%) 
Panitumumab 12 (41.4%) 
Minocycline use 8 (27.6%) 
Topical moisture use 19 (65.5%) 
Baseline CTCAE at VK1 site  
  Grade 1 19 (65.5%) 
 32 
  Grade 2 10 (34.5%) 
Baseline MASCC scale at VK1 site  
  0 1 (3.4%) 
  1A 1 (3.4%) 
  2A 17 (58.6%) 
  3A 10 (34.5%) 
BSA = body surface area; ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal 408 
growth factor receptor; CTCAE = Common Terminology Criteria for Adverse Events; MASCC 409 
= Multinational Association of Supportive Care in Cancer; VK = vitamin K 410 
  411 
 33 
Fig. 1 412 
  413 
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Fig. 2 414 
 415 
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Fig 4. 419 
 420 
  421 




  424 
Placebo start of treatment  Placebo end of treatment (8 weeks)  
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Fig. 5 425 
 426 
 427 
  428 
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Supplementary 429 
Table S1. MASCC scale 430 
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 
Papulopustular eruption 
(grading individually 
for face, scalp, chest, or 
back) 
1A 
Papules or pustules < 5 
or 
1 area of erythema or 
edema < 1 cm in size  
2A 
Papules or pustules 6–20 
or 
2–5 areas of erythema or edema < 1 
cm in size 
3A 
Papules or pustules > 20 
or 
More than five areas of erythema or 
edema < 1 cm in size 
- 
1B 2B 3B - 
 40 
Papules or pustules < 5 
or 
One area of erythema or 
edema < 1 cm in size and 
pain or pruritus 
Papules or pustules 6–20 
or 
2–5 areas of erythema or edema < 1 
cm in size and pain, pruritus, or effect 
on emotins or functioning 
Papules or pustules > 20 
or 
More than five areas of erythema or 
edema < 1 cm in size and pain, 
pruritus, or effect on emotins or 
functioning 
 431 
